Abstract |
In an attempt to further improve on the encouraging results achieved by high-dose cytosine arabinoside (HD AraC) and mitoxantrone (HAM) in refractory acute leukemias, a timely modified sequential schedule of both drugs was developed (S-HAM) and applied to 13 patients with far advanced acute leukemias, 8 of whom had been treated with the original HAM protocol before. Based on the cell kinetic and pharmacokinetic rationale outlined by Capizzi et al., HD AraC 3 g/m2 was applied every 12 h on days 1 and 2 followed by mitoxantrone 10 mg/m2/day on days 3 and 4. After 3 days without therapy the identical sequence was repeated on days 8 and 9 (HD AraC) and 10 and 11 ( mitoxantrone), respectively. Of the 13 patients 9 (69%) achieved a complete remission, 2 were resistant and 2 were early deaths. Six of the 8 patients with prior HAM treatment obtained a further complete remission with S-HAM. In 2 of these patients a longer remission was induced by S-HAM than by the preceding original HAM treatment. Although these data are preliminary and need confirmation on larger numbers of patients, they strongly suggest a high antileukemic activity of the S-HAM protocol which may even be superior to the previously used HAM regimen.
|
Authors | W Hiddemann, T Büchner, M Essink, O Koch, W Stenzinger, J van de Loo |
Journal | Onkologie
(Onkologie)
Vol. 11
Issue 1
Pg. 10-2
(Feb 1988)
ISSN: 0378-584X [Print] Switzerland |
PMID | 3283619
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Clinical Trials as Topic
- Cytarabine
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Leukemia, Lymphoid
(drug therapy)
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Middle Aged
- Mitoxantrone
(administration & dosage)
- Pilot Projects
|